Panhypopituitarism or partial pituitary failure. Diagnosis usually requires dynamic testing with insulin or glucagon stress to detect deficiency of either one or more anterior or posterior pituitary hormones.
This may indicate suboptimal glucocorticoid replacement.
General malaise may occur with suboptimal glucocorticoid replacement.
This may indicate suboptimal glucocorticoid replacement.
This may indicate suboptimal glucocorticoid replacement.
This may indicate suboptimal glucocorticoid replacement.
A drop in energy at particular times of day may suggest inadequate glucocorticoid replacement at that time and may be remedied by splitting or altering the timing of doses.
This may indicate supraphysiological glucocorticoid replacement.
This may indicate supraphysiological glucocorticoid replacement.
This may indicate supraphysiological glucocorticoid replacement.
Thinning of the skin, redness, acne, easy bruising and new striae may all indicate supraphysiological glucocorticoid replacement.
Tiredness and general malaise may occur with suboptimal thyroid hormone replacement.
This may indicate suboptimal thyroid hormone replacement.
This may indicate suboptimal thyroid hormone replacement.
This may indicate suboptimal thyroid hormone replacement.
This may indicate suboptimal thyroid hormone replacement.
Doughy, pallid and dry skin may indicate suboptimal thyroid hormone replacement. Diffuse hair loss may also occur.
In a hypopituitary patient on replacement therapy this may be the only symptom to indicate supraphysiological thyroid hormone replacement. Symptoms of frank hyperthyroidism are rare.
This may indicate supraphysiological thyroid hormone replacement, though this is rarely seen in hypopituitary patients.
This may indicate supraphysiological thyroid hormone replacement.
This may indicate supraphysiological thyroid hormone replacement, though in patients with pituiary disease, this usually indicates loss of gonadotropic function, and will also occur with hyperprolactinaemia.
This may indicate supraphysiological thyroid hormone replacement or more commonly, supraphysiological glucocorticoid replacement therapy.
Assess timing of stages of puberty: timing of secondary hair development and rate of change of height in all, breast development and menarche in females, increase in testicular and penile volume, early morning erections and voice breaking in males.
General malaise and lack of energy may indicate gonadotropin deficiency or inadequate replacement, particularly in male patients.
This may indicate gonadotropin deficiency or inadequate replacement.
Loss of libido occurs with gonadotropin deficiency or inadequate replacement.
This may indicate gonadotropin deficiency or inadequate replacement.
This may indicate gonadotropin deficiency or inadequate replacement.
This may indicate gonadotropin deficiency or inadequate replacement.
Secondary amenorrhoea occurs with hypogonadism.
If the patient has previously sought fertility without success, this may help time the onset of their disease.
Previous pregnancies imply that gonadotropic function was normal at that time.
Inability to breast feed may suggest Sheehan’s syndrome as the cause of hypopituitarism.
Pregnancy should always be excluded before investigation of amenorrhoea.
These may be secondary to gonadotropin deficiency.
Erectile dysfunction may be multi-factorial though loss of early morning erections is a more significant sign of hypogonadism.
Gynaecomastia may occur with hypogonadism and in particular with hyperprolactinaemia.
Frequency of shaving varies widely but is usually constant with an individual adult.
Increase in libido is most often encountered in women with high testosterone levels rather than excessive replacement.
This may indicate excessive testosterone replacement. Symptoms of over replacement with estrogen are not usually recognised.
Multiple, rather non-specific symptoms may occur in the syndrome of adult GH deficiency, though none are diagnostic of it. The QOL-AGHDA disease specific questionnaire has been specifically developed to seek symptoms of adult GH deficiency. Scores above 11/25 are required to qualify for GH replacement therapy according to NICE guidelines.
This is a commonly reported feature of adult GH deficiency.
This is a commonly reported feature of adult GH deficiency, as well as a general lack of energy and concentration.
This may occur in the syndrome of adult GH deficiency, and is most likely to be recognised by completing the QOL-AGHDA questionnaire.
This is a commonly reported feature of adult GH deficiency, as well as a general lack of energy and concentration.
This may occur in the syndrome of adult GH deficiency, though is obviously not specific to it.
This may be detected on close questioning.
Osteoporosis is more common in pituitary patients. It often occurs in the context of supraphysiological glucocorticoid replacement, though is also exacerbated by GH deficiency, or thyroxine excess.
Increased central adiposity, with loss of lean muscle bulk, may occur with GH deficiency.
This may improve with GH replacement.
This is a common complaint, particularly during initial dose titration.
This is a symptom of GH excess, but is rare in patients on replacement therapy.
This is a commonly encountered side effect of excessive GH replacement therapy, and should prompt dose reduction.
Prolactin deficiency is usually asymptomatic and is not specifically treated.
This may occur in multiple pituitary pathologies due to disinhibition of prolactin release. Symptoms are usually easily controlled with dopamine agonist therapy.
Diabetes insipidus is typified by unquenchable thirst for any fluid, with polyuria and nocturia.
Ask specifically whether they take a glass of water to bed with them, how many times they get up at night to pass urine, and when they wake do they drink before or after using the toilet?
In patients on replacement therapy, nasal desmopressin tends to control symptoms for approximately 16 hours. Symptoms occurring before this time require an increase in the size or frequency of desmopressin dose.
If the patient does not experience at least a short period of thirst during the day they are at risk of over-replacement and water overload.
If patients do not pass urine during the day, this indicates a risk of severe over-replacement, and a danger that the patient may develop water overload and hyponatraemia.
This may indicate severe over-replacement with hyponatraemia.
This may indicate severe over-replacement with hyponatraemia.
For the assessment of suspected new pituitary disease, see non functioning pituitary adenomas.
GH is often the first anterior pituitary hormone to be lost following pituitary damage. Radiotherapy is particularly associated with GH deficiency.
Radiotherapy is widely used and highly effective in cancer management, and many more adults are now survivors of previous cancer. However, cranial and craniospinal irradiation for childhood haematological malignancy, bone marrow transplants, or intracranial tumours, does increase the risk of hypopituitarism developing, and GH deficiency tends to be the first manifestation of this.
Even minor traumatic brain injury may be associated with late onset hypopituitarism. This is unpredictable in timing and severity, and may not correlate to the severity of percieved injury, loss of consciousness or the need for intensive care. Furthermore, this form of hypopituitarism does not respect the typical sequential loss of pituitary hormones seen following other non traumatic causes of hypopituitarism such as radiotherapy.
Estrogen replacement therapy of any preparation will lead to elevations in cortisol binding globulin and so effect serum cortisol results.
Inhaled and topical steroids also affect the hypothalamo-pituitary-adrenal axis, and steroids may occasionally be found in preparations thought by the patient to be 'natural' or 'herbal'.